Claims
- 1. A pharmacological composition comprising at least one ganglioside or portion thereof; wherein the pharmacological composition modulates the content of the ganglioside in the skin.
- 2. The pharmacological composition of claim 1 wherein the ganglioside is GM3, GT1b, 9-O-acetyl-GD3 or GD3.
- 3. The pharmacological composition of claim 1 wherein the ganglioside is a synthetic or semi-synthetic ganglioside having a truncated lipid moiety.
- 4. The pharmaceutical composition of claim 3 wherein the truncated lipid moiety contains from about 1 to about 17 carbons.
- 5. The pharmacological composition of claim 1 further comprising at least one agent that modulates ganglioside content or activity.
- 6. The pharmacological composition of claim 5 wherein said agent is a gene, an antisense nucleic acid, anti-ganglioside antibodies or antibodies directed to ganglioside binding sites.
- 7. The pharmacological composition of claim 1 further comprising a pharmacologically acceptable carrier.
RELATED APPLICATION INFORMATION
[0001] This application claims priority from U.S. application Ser. No. 60/254,387 filed Dec. 8, 2000.
GOVERNMENT RIGHTS
[0002] This invention was made with Government support under Grant No. AR-44619 awarded by the National Institutes of Health. The Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60254387 |
Dec 2000 |
US |